Touchstone International Medical Science Co.Ltd(688013)
Independent directors’ opinions on the 19th meeting of the first board of directors
Independent opinions on relevant matters
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, the rules of independent directors of listed companies and other laws and regulations, as well as the relevant provisions of the articles of association of Touchstone International Medical Science Co.Ltd(688013) and the working system of independent directors of the company, we are the independent directors of Touchstone International Medical Science Co.Ltd(688013) , After reviewing the relevant matters of the 19th meeting of the first board of directors of the company, based on the independent and objective position and in a prudent and responsible attitude, he expressed the following independent opinions on the relevant proposals of the meeting:
Independent opinions on repurchase of shares of the company by means of centralized bidding transaction
1. The shares repurchased by the company this time comply with the relevant provisions of laws, regulations and normative documents such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the opinions on supporting the repurchase of shares by listed companies, the rules for the repurchase of shares by listed companies, the guidelines for the self discipline supervision of listed companies No. 7 – share repurchase, The voting procedures of the board meeting shall comply with relevant laws, regulations and the articles of association.
2. The maximum share repurchase amount of RMB 100 million will not have a significant impact on the company’s operation, finance and future development. The company is able to pay the repurchase price. After the repurchase, the equity distribution of the company meets the conditions of the listed company and will not affect the listing status of the company.
3. The implementation of the company’s share repurchase is conducive to safeguarding the interests of the company and shareholders, establishing and improving the company’s long-term incentive mechanism, fully mobilizing the enthusiasm of the company’s employees, and promoting the healthy and sustainable development of the company. The company’s share repurchase is necessary.
4. The company plans to use its own funds for this repurchase. This repurchase will not have a significant impact on the company’s operation, finance and future development, and will not lead to the company’s equity distribution not meeting the listing conditions. The share repurchase scheme is feasible.
5. This repurchase is carried out in the form of centralized bidding transaction, and there is no situation that damages the interests of the company and all shareholders, especially small and medium-sized shareholders.
In conclusion, we believe that the company’s share repurchase is legal and compliant, and the repurchase plan is feasible and necessary, which is in line with the interests of the company and all shareholders.
Touchstone International Medical Science Co.Ltd(688013) independent directors: Lu Zhian, fan Ming, Jin Wenlong (no text below)
